ScripChina’s public healthcare service payer, the National Healthcare Security Administration (NHSA), kept the level of drug price cuts steady at an average of roughly 60% in its latest round of annual neg
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Simcere Acquires China-Plus Rights To G